Targeting FLT3 mutations in AML: review of current knowledge and evidence

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

(2018) Jorge Cortes et al.   LANCET ONCOLOGY

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Margaret R. O'Donnell et al.   Journal of the National Comprehensive Cancer Network

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure

(2017) M Wattad et al.   LEUKEMIA

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

(2017) R F Schlenk et al.   LEUKEMIA

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

(2016) Anthony D. Ho et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia

(2016) Betül Oran et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

(2016) A. K. Burnett et al.   BLOOD

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

(2016) Lauren Y. Lee et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

(2016) Elie Traer et al.   CANCER RESEARCH

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

(2016) V I Gaidzik et al.   LEUKEMIA

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improvement in clinical outcome ofFLT3ITD mutated acute myeloid leukemia patients over the last one and a half decade

(2015) Talha Badar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Secondary mutations as mediators of resistance to targeted therapy in leukemia

(2015) N. Daver et al.   BLOOD

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations

(2015) Walter Fiedler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rates of complete diagnostic testing for patients with acute myeloid leukemia

(2015) Tara L. Lin et al.   Cancer Medicine

Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis

(2014) M. Port et al.   ANNALS OF HEMATOLOGY

Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia

(2014) Michael R. Grunwald et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

(2014) D. C. Linch et al.   BLOOD

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

(2014) F Ravandi et al.   LEUKEMIA

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

(2013) J. Kronke et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

(2013) Neil P. Shah et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase

(2013) Xiaochuan Yang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers

(2013) Catherine Dutreix et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells

(2013) R. N. Gunawardane et al.   MOLECULAR CANCER THERAPEUTICS

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

(2013) M. Levis   Hematology-American Society of Hematology Education Program

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

(2012) A. Nazha et al.   HAEMATOLOGICA

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients

(2012) Mikako Warren et al.   MODERN PATHOLOGY

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia

(2011) David Grimwade et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Identification ofN-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

(2009) Qi Chao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Acquired copy number alterations in adult acute myeloid leukemia genomes

(2009) M. J. Walter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD